Pharmaceutical product permissions

A searchable record of what Walter is equipped to evaluate.

Explore compositions across oral solids, oral liquids, sterile injectables, topical formats and selected specialist presentations. Use the catalogue to begin a technical and commercial discussion—not as a substitute for written facility-specific confirmation.

5,500Distinct records
21Dosage forms
407Sterile injectable records
17Therapeutic indexes

Built for portfolio teams

Move from a molecule search to a focused feasibility conversation.

The catalogue brings together composition, strength, pharmacological class, dosage form, manufacturing stream, BCS class and documented regulatory references. It also incorporates products listed in Walter’s March 2025 Injectables Manufacturing Profile. Therapeutic and pharmacological classes are practical navigation labels; final indication, regulatory position and site suitability are confirmed product by product.

Search the catalogue

Selected catalogue briefs

Explore a composition for your manufacturing brief.

Browse selected compositions by dosage form, then share the required strength, pack, quantities and target market for a product-specific feasibility review.

Search the full catalogue
Browse 26 selected composition briefs

Therapeutic index

Begin with the treatment area.

Each composition is assigned to one practical primary area for navigation. Combination products may span more than one clinical use and remain subject to product-specific review.

Searchable permissions catalogue

Find a composition, dosage form or capability route.

5,500distinct permission records

Loading full catalogue search…
Therapeutic area
Dosage-form family
Specific dosage form
Pharmacological class
Manufacturing stream
BCS classification
Confirmed CDSCO category
Drugs Rules status

24 records shown

CardiovascularPRM 4622
Dosage formHard-gelatin capsules
Oral

Acebutolol Hcl 100 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Beta blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 4623
Dosage formHard-gelatin capsules
Oral

Acebutolol Hcl 200 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Beta blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 4624
Dosage formHard-gelatin capsules
Oral

Acebutolol Hcl 400 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Beta blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 4627
Dosage formHard-gelatin capsules
Oral

Acipimox 250 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Nicotinic acid lipid-lowering agent
Manufacturing stream
Non-beta-lactam
BCS class
Not specified
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 1975
Dosage formDry-powder injectables
Parenteral

Adenosine 3000 mg

Route
Parenteral
Formulation type
Sterile powder for injection
Pharmacological class
Antiarrhythmic
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Parenteral
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2649
Dosage formTablets
Oral

Aliskiren 150 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Direct renin inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2650
Dosage formTablets
Oral

Aliskiren 150 mg, Amlodipine 10 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Calcium-channel blocker + Direct renin inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2651
Dosage formTablets
Oral

Aliskiren 150 mg, Amlodipine 5 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Calcium-channel blocker + Direct renin inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2652
Dosage formTablets
Oral

Aliskiren 150 mg, Valsartan 300 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Angiotensin II receptor blocker + Direct renin inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2653
Dosage formTablets
Oral

Aliskiren 160 mg, Valsartan 320 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Angiotensin II receptor blocker + Direct renin inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2654
Dosage formTablets
Oral

Aliskiren 300 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Direct renin inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2655
Dosage formTablets
Oral

Aliskiren 300 mg, Amlodipine 10 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Calcium-channel blocker + Direct renin inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2656
Dosage formTablets
Oral

Aliskiren 300 mg, Amlodipine 5 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Calcium-channel blocker + Direct renin inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2657
Dosage formTablets
Oral

Almitrine 30 mg, Raubasine 10 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Ergot alkaloid vascular agent + Respiratory stimulant
Manufacturing stream
Non-beta-lactam
BCS class
Not specified
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 0110
Dosage formTablets
Oral

Alprazolam 0.25 mg, Propranolol 20 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Anxiolytic
Manufacturing stream
Non-beta-lactam
BCS class
Class I
Drugs Rules status
Schedule H1Listed substance
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2689
Dosage formTablets
Oral

Ambrisentan 10 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Endothelin receptor antagonist
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2690
Dosage formTablets
Oral

Ambrisentan 5 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Endothelin receptor antagonist
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2705
Dosage formTablets
Oral

Amiloride 5 mg, Frusemide 20 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Loop diuretic + Potassium-sparing diuretic
Manufacturing stream
Non-beta-lactam
BCS class
Class IV (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2706
Dosage formTablets
Oral

Amiloride 5 mg, Frusemide 40 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Loop diuretic + Potassium-sparing diuretic
Manufacturing stream
Non-beta-lactam
BCS class
Class IV (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2707
Dosage formTablets
Oral

Amiloride 5 mg, Hydrochlorothiazide 50 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Potassium-sparing diuretic + Thiazide / thiazide-like diuretic
Manufacturing stream
Non-beta-lactam
BCS class
Class IV (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 0128
Dosage formTablets
Oral

Amiloride 5 mg, Torsemide 10 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Diuretic
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Drugs Rules status
Schedule HList or category match
CDSCO categoryFDC
Documented match

Listed in CDSCO FDC approval records

CDSCO filing reference · page 532
CardiovascularPRM 2709
Dosage formTablets
Oral

Amiodarone Hcl 100 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antiarrhythmic
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2710
Dosage formTablets
Oral

Amiodarone Hcl 200 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antiarrhythmic
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 0141
Dosage formTablets
Oral

Amlodipine 10 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antihypertensive
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Drugs Rules status
Schedule HList or category match
CDSCO categoryNew Drug
Documented match

Listed in CDSCO New Drug approval records

CDSCO filing reference · page 899

Explore the product catalogue

Browse product pages by therapeutic area.

Browse compositions, strengths and dosage forms for third-party and contract manufacturing enquiries. Each product page includes its catalogue specification, manufacturing and packaging considerations, and a product-specific enquiry link. Confirm the applicable unit, documents and commercial terms with Walter.

How to read this catalogue

Permission is a starting point—not a supply commitment.

01

Therapeutic index

Primary areas provide buyer-friendly navigation. Combination products may reasonably sit across several clinical categories.

02

Facility confirmation

Current licence scope, site allocation, equipment fit and applicable segregation requirements are checked before commitment.

03

Product feasibility

Formula, strength, presentation, pack, target market, testing requirements and commercial scale are assessed together.

04

Responsible use

This B2B catalogue is not prescribing information, patient guidance or a representation that every composition is currently available for sale.

Start the conversation

Found a composition worth discussing?

Use the enquiry link on any record to carry its composition and dosage form into your manufacturing brief.

Request a quote
Quick chat on WhatsAppLet’s discuss your product